VSTM - Verastem Inc Stock Price, Fair Value and News

9.94USD+0.31 (+3.22%)Market Closed

Market Summary

USD9.94+0.31

Market Closed

3.22%

VSTM Stock Price

View Fullscreen

VSTM RSI Chart

VSTM Valuation

Market Cap

251.4M

Price/Earnings (Trailing)

-2.88

Price/Sales (Trailing)

102.31

EV/EBITDA

-2.99

Price/Free Cashflow

-2.91

VSTM Price/Sales (Trailing)

VSTM Profitability

EBT Margin

-2843.30%

Return on Equity

-152.28%

Return on Assets

-58.35%

Free Cashflow Yield

-34.39%

VSTM Fundamentals

VSTM Revenue

Revenue (TTM)

2.6M

VSTM Earnings

Earnings (TTM)

-87.4M

Earnings Growth (Yr)

-62.83%

Earnings Growth (Qtr)

-36.81%

Breaking Down VSTM Revenue

Last 7 days

-1.4%

Last 30 days

-18.6%

Last 90 days

-18.0%

Trailing 12 Months

104.8%

How does VSTM drawdown profile look like?

VSTM Financial Health

Current Ratio

5.45

Debt/Equity

0.38

Debt/Cashflow

-4.01

VSTM Investor Care

Shares Dilution (1Y)

59.58%

Diluted EPS (TTM)

-3.93

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2022	2.4M	2.8M	3.1M	2.6M
2021	66.9M	45.3M	23.7M	2.1M
2020	20.8M	22.0M	91.6M	88.5M
2019	24.4M	22.1M	19.8M	17.5M
2018	0	0	0	26.7M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Verastem Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Apr 05, 2024	calkins daniel	sold	-65.22	10.87	-6.00	chief financial officer
Mar 25, 2024	calkins daniel	sold	-300	12.02	-25.00	chief financial officer
Mar 20, 2024	calkins daniel	sold	-608	11.07	-55.00	chief financial officer
Mar 19, 2024	stuglik brian m	sold	-2,833	10.38	-273	-
Mar 19, 2024	paterson dan	sold	-1,889	10.38	-182	president and ceo
Mar 19, 2024	gagnon robert e.	sold	-1,349	10.38	-130	-
Mar 18, 2024	stuglik brian m	sold	-5,751	10.71	-537	-
Mar 18, 2024	paterson dan	sold	-2,613	10.71	-244	president and ceo
Mar 18, 2024	gagnon robert e.	sold	-3,030	10.71	-283	-
Feb 06, 2024	gagnon robert e.	sold	-126,095	13.7	-9,204	-

Which funds bought or sold VSTM recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 25, 2024	SIMPLEX TRADING, LLC	reduced	-77.63	-7,000	3,000	-%
Apr 25, 2024	Bank of New York Mellon Corp	sold off	-100	-93,602	-	-%
Apr 24, 2024	PSI Advisors, LLC	unchanged	-	99.00	319	-%
Apr 24, 2024	AlphaCentric Advisors LLC	sold off	-100	-1,221,000	-	-%
Apr 23, 2024	Global Retirement Partners, LLC	unchanged	-	6.00	94.00	-%
Apr 23, 2024	LORING WOLCOTT & COOLIDGE FIDUCIARY ADVISORS LLP/MA	unchanged	-	-5,928	28,723	-%
Apr 22, 2024	Vivo Capital, LLC	unchanged	-	5,630,770	18,153,800	1.43%
Apr 17, 2024	Cannon Global Investment Management, LLC	new	-	130,980	130,980	0.35%
Mar 11, 2024	VANGUARD GROUP INC	unchanged	-	11,502	9,363,060	-%
Mar 01, 2024	GOLDMAN SACHS GROUP INC	added	17.59	53,452	354,888	-%

Are Funds Buying or Selling VSTM?

Are funds buying VSTM calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own VSTM

No. of Funds

Unveiling Verastem Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	biotechnology value fund l p	5.4%	1,394,241	SC 13G/A
Feb 14, 2024	viking global investors lp	9.99%	2,531,829	SC 13G/A
Feb 14, 2024	orbimed advisors llc	6.1%	1,529,115	SC 13G/A
Feb 13, 2024	vivo opportunity, llc	6.1%	1,538,461	SC 13G/A
Feb 02, 2024	soleus capital master fund, l.p.	6.8%	1,425,634	SC 13G/A
Aug 31, 2023	adage capital partners gp, l.l.c.	5.15%	1,300,000	SC 13G
Aug 10, 2023	baker bros. advisors lp	0.0%	0	SC 13G/A
Jul 27, 2023	soleus capital master fund, l.p.	5.1%	1,297,369	SC 13G
Jun 23, 2023	flynn james e	6.10%	1,538,461	SC 13G
Jun 12, 2023	baker bros. advisors lp	8.0%	1,345,192	SC 13G/A

Recent SEC filings of Verastem Inc

View All Filings

Date Filed	Form Type	Document
Apr 12, 2024	DEF 14A	DEF 14A
Apr 09, 2024	8-K	Current Report
Apr 08, 2024	4	Insider Trading
Mar 27, 2024	4	Insider Trading
Mar 21, 2024	4	Insider Trading
Mar 20, 2024	4	Insider Trading
Mar 20, 2024	4	Insider Trading
Mar 20, 2024	4	Insider Trading
Mar 14, 2024	10-K	Annual Report
Mar 14, 2024	S-8	Employee Benefits Plan

Peers (Alternatives to Verastem Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	42.1B	6.8B	4.75%	-16.01%	-8.94	6.15	-64.45%	-156.37%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	18.1B	1.8B	-1.40%	-26.02%	-41.18	9.92	76.23%	61.08%
BMRN	15.3B	2.5B	-5.97%	-14.48%	74.64	6.2	13.74%	186.89%
INCY	11.7B	3.7B	-7.74%	-29.36%	19.56	3.16	8.87%	75.42%
MID-CAP
APLS	5.3B	396.6M	-18.63%	-42.67%	-10.08	13.43	425.83%	18.94%
BBIO	4.5B	-	-17.63%	75.41%	-6.9	60.35	54.84%	-34.79%
AXSM	3.5B	270.6M	-7.66%	3.02%	-14.61	12.91	440.80%	-27.84%
ARWR	2.8B	240.7M	-19.13%	-34.68%	-9.44	12.18	-1.03%	-92.09%
ACAD	2.8B	726.4M	-7.52%	-19.83%	-44.93	3.79	40.45%	71.62%
SMALL-CAP
CPRX	1.8B	398.2M	-4.45%	-4.33%	24.84	4.45	85.90%	-14.05%
NVAX	606.0M	983.7M	-10.25%	-44.07%	-1.11	0.62	-50.36%	17.16%
CRBP	388.7M	881.7K	-9.17%	305.92%	-8.71	466.16	-77.61%	-5.33%
INO	267.6M	4.9M	-17.15%	24.46%	-1.98	54.99	-54.97%	51.71%
IBIO	6.0M	2.1M	-59.11%	53.70%	-0.22	2.14	-13.45%	66.37%

Verastem Inc News

Latest updates

Verastem Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4	2018Q3	2018Q2
Revenue	-	-	-	-	2,596,000	545,000	522,500	500,000	503,000	506,000	78,647,000	4,307,000	5,056,000	3,617,000	9,032,000	3,136,000	1,671,000	8,589,500	15,508,000	10,000,000
Costs and Expenses	-4.9%	16,846,000	17,709,000	21,402,000	19,576,000	17,056,000	14,848,000	16,444,000	15,114,000	17,260,000	63,630,000	25,571,000	31,415,000	36,908,000	35,135,000	41,413,000	36,341,000	35,469,000	37,077,000	28,194,000
Operating Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	36,341,000	35,469,000	37,077,000	28,194,000
S&GA Expenses	-4.9%	6,106,000	6,421,000	6,514,000	5,934,000	5,660,000	5,523,000	6,714,000	6,218,000	7,095,000	20,614,000	15,442,000	19,604,000	23,728,000	22,153,000	29,298,000	26,033,000	26,199,000	25,426,000	15,813,000
R&D Expenses	-4.9%	10,740,000	11,288,000	14,888,000	13,642,000	11,396,000	9,325,000	9,730,000	8,896,000	10,153,000	10,955,000	9,344,000	10,924,000	12,455,000	12,219,000	11,346,000	9,758,000	8,762,000	11,571,000	12,381,000
EBITDA Margin	-24.3%	-27.57	-22.18	-22.46	-25.66	-29.72	-2.37	-1.37	-0.91	-0.58	-	-	-	-	-	-	-	-	-	-
Interest Expenses	1.0%	724,000	717,000	640,000	56,000	10,000	7,980,000	1,007,000	975,000	1,354,000	1,898,000	1,868,000	10,674,000	5,453,000	5,041,000	5,185,000	4,929,000	3,952,000	862,000	516,000
Income Taxes	-	-	-	-	-	-194,000	-	-	-	194,000	-	-	-	-	-	-	-	-	-	-
Earnings Before Taxes	-	-	-	-	-	-41,658,000	-	-	-	-19,670,000	13,138,000	-23,010,000	-37,990,000	-	-	-	-	-	-	-
EBT Margin	-25.4%	-28.43	-22.67	-25.63	-29.47	-34.68	-2.85	-1.49	-1.01	-0.76	-	-	-	-	-	-	-	-	-	-
Net Income	7.1%	-16,808,000	-18,090,000	-21,952,000	-16,962,000	-16,481,000	-22,786,000	-16,902,000	-15,031,000	-19,864,000	13,138,000	-23,010,000	-37,990,000	-38,774,000	-30,139,000	-42,194,000	-38,102,000	-11,349,000	-21,668,000	-18,367,000
Net Income Margin	-21.5%	-28.43	-23.40	-28.14	-30.27	-34.68	-3.15	-0.85	-0.67	-0.77	-	-	-	-	-	-	-	-	-	-
Free Cashflow	-10.2%	-16,616,000	-15,082,000	-12,694,000	-19,281,000	-9,933,000	-10,827,000	-13,424,000	-19,514,000	-21,703,000	44,741,000	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	-15.0%	150	176	192	121	95.00	111	100	116	109	112	124	137	154	218	199	208	145	193	219	243	277
Current Assets	-17.7%	144	174	190	119	93.00	109	98.00	113	106	109	115	128	145	189	145	149	85.00	167	192	217	253
Cash Equivalents	-18.0%	78.00	95.00	183	97.00	75.00	79.00	64.00	47.00	21.00	25.00	25.00	36.00	68.00	206	161	171	79.00	104	114	92.00	131
Inventory	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	6.00	4.00	3.00	0.00	0.00	0.00	0.00
Net PPE	5.7%	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00
Liabilities	-0.9%	71.00	72.00	69.00	67.00	48.00	48.00	47.00	43.00	21.00	16.00	36.00	34.00	39.00	88.00	84.00	85.00	138	171	169	155	153
Current Liabilities	10.8%	26.00	24.00	21.00	22.00	22.00	22.00	20.00	17.00	19.00	14.00	13.00	12.00	17.00	38.00	29.00	26.00	30.00	31.00	31.00	29.00	37.00
Shareholder's Equity	-31.0%	57.00	83.00	102	33.00	47.00	63.00	54.00	73.00	88.00	96.00	88.00	103	115	130	114	123	7.00	22.00	49.00	88.00	124
Retained Earnings	-3.4%	-824	-797	-777	-753	-737	-720	-702	-680	-663	-647	-624	-607	-592	-572	-585	-562	-524	-486	-455	-413	-375
Additional Paid-In Capital	0.2%	882	881	879	786	785	784	757	754	751	743	713	710	708	702	700	686	532	507	505	502	500
Shares Outstanding	0.1%	25.00	25.00	25.00	17.00	17.00	16.00	16.00	16.00	15.00	15.00	14.00	14.00	13.00	-	-	-	-	-	-	-	-
Float	-	-	-	187	-	216	-	-	-	-	-	697	-	-	-	291	-	-	-	111	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	-78.9%	-29,681	-16,589	-19,904	-20,286	-16,616	-15,082	-12,694	-19,281	-9,933	-10,827	-13,424	-19,318	-21,703	44,747	-22,547	-34,003	-37,221	-27,848	-34,669	-38,780	-19,188
Share Based Compensation	5.3%	1,598	1,517	1,432	1,313	1,287	1,356	1,758	1,646	1,574	1,987	2,170	1,980	2,933	2,156	1,659	1,370	1,311	1,915	3,065	2,248	1,763
Cashflow From Investing	117.7%	12,436	-70,079	14,000	-804	13,025	4,647	29,249	19,264	66.00	10,000	2,393	-12,372	-79,380	-6.00	-27.00	32,050	25,126	17,594	46,530	363	-126,803
Cashflow From Financing	49.9%	-446	-891	91,481	44,050	-	25,624	708	25,452	6,805	169	489	-578	-36,606	137	12,678	93,421	-12,704	494	9,694	75.00	145,469

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

VSTM Income Statement

2023-12-31

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Revenue:
Total revenue		$ 2,596	$ 2,053
Operating expenses:
Research and development	$ 61,356	50,558	39,347
Selling, general and administrative	30,728	24,975	24,115
Total operating expenses	92,084	75,533	63,462
Loss from operations	(92,084)	(72,937)	(61,409)
Other income (expense)	(109)	47
Interest income	6,214	1,215	181
Interest expense	(4,139)	(2,137)	(9,972)
Change in fair value of preferred stock tranche liability	2,751
Net loss	$ (87,367)	$ (73,812)	$ (71,200)
Net loss per share-basic	$ (3.96)	$ (4.57)	$ (4.90)
Net loss per share-diluted	$ (3.93)	$ (4.57)	$ (4.90)
Weighted average common shares outstanding used in computing net loss per share - basic	22,054	16,138	14,535
Weighted average common shares outstanding used in computing net loss per share - diluted	22,054	16,138	14,535
Net Income (Loss)	$ (87,367)	$ (73,812)	$ (71,200)
Unrealized gain (loss) on available-for-sale securities	13	(34)	(19)
Comprehensive loss	$ (87,354)	(73,846)	(71,219)
Sale of COPIKTRA license and related assets
Revenue:
Total revenue		$ 2,596	1,447
Transition Services Revenue
Revenue:
Total revenue			$ 606

VSTM Balance Sheet

2023-12-31

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 77,909	$ 74,933
Short-term investments	59,220	12,961
Accounts receivable, net		31
Prepaid expenses and other current assets	6,553	4,945
Total current assets	143,682	92,870
Property and equipment, net	37	92
Right-of-use asset, net	1,171	1,789
Restricted cash	241	241
Other assets	4,587	58
Total assets	149,718	95,050
Current liabilities:
Accounts payable	7,184	4,901
Accrued expenses	17,928	14,983
Deferred liabilities	327	710
Lease liability, short-term	941	794
Total current liabilities	26,380	21,663
Non-current liabilities:
Long-term debt	40,086	24,526
Lease liability, long-term	530	1,470
Preferred stock tranche liability	4,189
Total liabilities	71,185	47,659
Convertible Preferred Stock:
Convertible preferred stock	21,159
Stockholders' equity:
Preferred stock, value
Common stock, $0.0001 par value; 300,000 shares authorized, 25,281 and 16,712 shares issued and outstanding at December 31, 2023 and December 31, 2022, respectively	3	2
Additional paid-in capital	882,248	784,912
Accumulated other comprehensive income	13
Accumulated deficit	(824,890)	(737,523)
Total stockholders' equity	57,374	47,391
Total liabilities, convertible preferred stock and stockholders' equity	$ 149,718	$ 95,050

About Verastem Inc

Verastem, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer. Its product in development includes VS-6766, a rapidly accelerated fibrosarcoma (RAF)/mitogen-activated protein kinase (MEK) clamp that blocks MEK kinase activity and the ability of RAF to phosphorylate MEK. The company also engages in developing RAMP 201, an adaptive two-part multicenter, parallel cohort, randomized open label trial to evaluate the efficacy and safety of avutometinib and in combination with defactinib, an oral small molecule inhibitor of focal adhesion kinase (FAK) in patients with recurrent low grade serous ovarian cancer; and RAMP 202, which is in Phase 2 trial to evaluate the safety of VS-6766 in combination with defactinib in patients with KRAS and BRAF mutant non-small cell lung cancer following treatment with a platinum-based regimen and immune checkpoint inhibitor. Verastem, Inc. has license agreements with Chugai Pharmaceutical Co., Ltd. for the development, commercialization, and manufacture of products containing avutometinib; and Pfizer Inc. to research, develop, manufacture, and commercialize products containing Pfizer's inhibitors of FAK for therapeutic, diagnostic, and prophylactic uses in humans. In addition, it has a clinical collaboration agreement with Amgen, Inc. to evaluate the combination of avutometinib with Amgen's KRAS-G12C inhibitor LUMAKRASTM which in Phase 1/2 trial entitled RAMP 203; and a discovery and development collaboration with GenFleet Therapeutics to advance new programs targeting RAS pathway-driven cancers. The company was incorporated in 2010 and is headquartered in Needham, Massachusetts.

CEO	Mr. Daniel W. Paterson
WEBSITE	verastem.com
INDUSTRY	Biotechnology
EMPLOYEES	57

Verastem Inc Frequently Asked Questions

What is the ticker symbol for Verastem Inc? What does VSTM stand for in stocks?

VSTM is the stock ticker symbol of Verastem Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Verastem Inc (VSTM)?

As of Mon Apr 29 2024, market cap of Verastem Inc is 243.6 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of VSTM stock?

You can check VSTM's fair value in chart for subscribers.

What is the fair value of VSTM stock?

You can check VSTM's fair value in chart for subscribers. The fair value of Verastem Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Verastem Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for VSTM so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Verastem Inc a good stock to buy?

The fair value guage provides a quick view whether VSTM is over valued or under valued. Whether Verastem Inc is cheap or expensive depends on the assumptions which impact Verastem Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for VSTM.

What is Verastem Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Mon Apr 29 2024, VSTM's PE ratio (Price to Earnings) is -2.79 and Price to Sales (PS) ratio is 102.31. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. VSTM PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Verastem Inc's stock?

In the past 10 years, Verastem Inc has provided -0.206 (multiply by 100 for percentage) rate of return.